Maher Masoud Buys 75,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

Key Points

• CEO Maher Masoud of MaxCyte, Inc. purchased 75,000 shares at an average cost of $1.37 per share, totaling approximately $102,750, increasing his ownership to 175,000 shares.
• MaxCyte's stock recently saw an 8.7% increase, trading at $1.38, while the company has reported a negative EPS of ($0.12) for the last quarter.
• Multiple institutional investors have increased their stakes in MaxCyte, raising institutional ownership to 68.81% of the company's stock.

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) CEO Maher Masoud purchased 75,000 shares of MaxCyte stock in a transaction dated Wednesday, August 13th. The stock was acquired at an average cost of $1.37 per share, with a total value of $102,750.00. Following the completion of the acquisition, the chief executive officer directly owned 175,000 shares in the company, valued at approximately $239,750. This trade represents a 75.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

MaxCyte Stock Up 1.1%

Shares of MXCT stock traded up $0.02 during mid-day trading on Monday, reaching $1.38. The company's stock had a trading volume of 168,880 shares, compared to its average volume of 771,797. The company's 50 day simple moving average is $2.07 and its 200-day simple moving average is $2.67. MaxCyte, Inc. has a 12-month low of $1.26 and a 12-month high of $5.20. The firm has a market capitalization of $146.59 million, a PE ratio of -3.20 and a beta of 1.23.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). The firm had revenue of $8.51 million for the quarter, compared to analyst estimates of $9.57 million. MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%. As a group, research analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on MXCT. William Blair downgraded shares of MaxCyte from an "outperform" rating to a "market perform" rating in a report on Thursday, August 7th. Stephens assumed coverage on shares of MaxCyte in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $6.00 target price for the company. Wall Street Zen cut MaxCyte from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Finally, BTIG Research reissued a "neutral" rating on shares of MaxCyte in a research report on Monday, August 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $7.00.

Institutional Investors Weigh In On MaxCyte

Several hedge funds and other institutional investors have recently bought and sold shares of MXCT. Farther Finance Advisors LLC grew its holdings in MaxCyte by 7,935.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company's stock worth $26,000 after acquiring an additional 11,665 shares in the last quarter. CWM LLC lifted its stake in MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company's stock valued at $26,000 after buying an additional 5,836 shares during the last quarter. Prudential Financial Inc. bought a new stake in MaxCyte in the 2nd quarter valued at about $26,000. May Hill Capital LLC acquired a new position in shares of MaxCyte during the second quarter worth approximately $27,000. Finally, Tower Research Capital LLC TRC boosted its position in MaxCyte by 123.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock worth $31,000 after acquiring an additional 4,173 shares during the period. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.